Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. [electronic resource]
Producer: 20100903Description: 733-40 p. digitalISSN:- 1474-5488
- Adult
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors -- administration & dosage
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols
- Bevacizumab
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Drug-Related Side Effects and Adverse Reactions
- Female
- Humans
- Intention to Treat Analysis
- Lung Neoplasms -- drug therapy
- Male
- Middle Aged
- Survival Analysis
No physical items for this record
Publication Type: Clinical Trial, Phase IV; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.